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Retroviral RNA encapsidation is mediated by specific interactions between viral Gag proteins and cis-acting packaging sequences in
genomic RNA. Feline immunodeficiency virus (FIV) RNA encapsidation determinants have been shown to be discrete and noncontinuous,
comprising one region at the 5V end of the genomic mRNA (R-U5) and another region that mapped within the proximal 311 nt of gag. To aid
comparative understanding of lentiviral encapsidation and refinement of FIV vector systems, we used RNase protection assays (RPAs) of
cellular and virion RNAs to investigate in detail the gag element. mRNAs of subgenomic vectors as well as of full-length molecular clones were
optimally packaged into viral particles and resulted in high-titer FIV vectors when they contained only the proximal 230 nucleotides (nt) of gag.
Further 3V truncations of gag sequences progressively diminished encapsidation and transduction. Deletion of the initial ninety 5V nt of the gag
gene abolished mRNA packaging, demonstrating that this segment is indispensable for encapsidation. Focusing further on this proximal
sequence, we found that a deletion of only 13 nt at the 5V end of gag impaired encapsidation of subgenomic vector and proviral RNAs.
D 2004 Elsevier Inc. All rights reserved.Keywords: Feline immunodeficiency virus (FIV); Human immunodeficiency virus (HIV); Packaging signal; Encapsidation; gag; Lentiviral vectorIntroduction
During retroviral assembly, two copies of viral genomic
mRNA are incorporated into the nascent viral particle. This
process is highly selective in that only unspliced, genomic
RNA is encapsidated, whereas spliced (subgenomic) and
cellular RNAs are excluded from virions. The specificity of
packaging depends on direct binding interactions between
the viral Gag polyprotein and cis-acting viral RNA sequen-
ces (Berkowitz et al., 1996; Jewell and Mansky, 2000; Lever
et al., 1991; Linial and Miller, 1990; Sakalian and Hunter,
1998; Swanstrom and Wills, 1997). In mammalian retro-
viruses, the RNA sequences that participate in these specific
interactions are located in a region that encompasses vari-
able portions of the 5V untranslated region and usually
extend into the proximal gag open reading frame (ORF;
Linial and Miller, 1990). Because sequences downstream of
the major splice donor (MSD) and within gag are present0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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encapsidation of genomic RNA. However, there are reports
showing that in simian immunodeficiency virus (SIV), the
major packaging determinants are upstream of the MSD
(Patel et al., 2003; Strappe et al., 2003). The principal
identified packaging determinant in the ASLV group of
avian retroviruses is located upstream of the MSD (Banks
and Linial, 2000; Katz et al., 1986). Nevertheless, full-
length ASLV RNA is highly favored over subgenomic
mRNAs for encapsidation, a paradox that remains unex-
plained (Banks et al., 1998).
In human immunodeficiency virus type 1 (HIV-1) and
HIV-2, deletion of the region between the MSD and the gag
start codon impairs encapsidation and blocks productive
replication (Aldovini and Young, 1990; Lever et al., 1989;
Poeschla et al., 1998). Four RNA stem-loops that span the
MSD (SL1-4) are required for efficient HIV mRNA encap-
sidation (Berglund et al., 1997; Berkowitz and Goff, 1994;
Clever and Parslow, 1997; Harrison and Lever, 1992;
Harrison et al., 1998; McBride and Panganiban, 1996,
1997; McBride et al., 1997). RNA mapping experiments
suggest that additional encapsidation determinants are pres-
ent throughout the 5V end of the mRNA, including U5
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and Panganiban, 1997; McBride et al., 1997; Vicenzi et al.,
1994), a situation that parallels that of feline immunode-
ficiency virus (FIV) (Kemler et al., 2002). HIV-1 encap-
sidation determinants are known to extend into gag
(Buchschacher and Panganiban, 1992; Luban and Goff,
1994; Parolin et al., 1994), and HIV-1 transfer vectors used
in gene therapy applications generally contain about 350 nt
of gag sequences (Dull et al., 1998). Only a few attempts
have been made to further characterize the HIV-1 gag
determinant in direct RNA encapsidation assays (Luban
and Goff, 1994; Parolin et al., 1994). These studies
suggested that the first 40 nt of gag contain elements
important for RNA packaging or vector propagation.
Nevertheless, HIV-1 gag determinants involved in mRNA
packaging are not well characterized.
In an initial mapping of FIV encapsidation determinants
(Kemler et al., 2002), we found that in contrast to HIV and
other mammalian retroviruses, the MSD–gag interval
contributes negligibly to FIV encapsidation, and deletions
in this region did not prevent viral replication. In addition,
the 311 proximal nucleotides of FIV gag were necessary
but not sufficient for encapsidation. This gag determinant
must clearly be paired with a second determinant upstream
of the MSD because deletions there, particularly in U5,
markedly reduced encapsidation. No significant encapsida-
tion determinants appear to exist 3V of gag nt 311.
Another report is in general agreement with these results
(Browning et al., 2003a).
FIV-based lentiviral vectors effectively transduce cells in
multiple organ systems (Poeschla, 2003). Development of
optimal replication-defective vector systems requires defin-
ing the minimum sequences that are necessary and sufficient
for RNA encapsidation. This information allows for transfer
vector minimization, which reduces risk of replication-
competent retrovirus formation. Because the main determi-
nant selecting FIV genomic RNA for packaging over
spliced RNA lies within gag and because this sequence
generates overlap with Gag-encoding sequences in the
packaging construct, we decided to further characterize
and minimize the encapsidation determinants in the gag
element. Here we use a competitive encapsidation assay to
test subgenomic vectors and proviral clones harboring
mutant gag sequences for their ability to compete with the
full-length wild-type FIV transcripts in RNA packaging, and
correlate these data with the transduction efficiencies of the
vectors.Results and discussion
The proximal 230 nt of gag are necessary for encapsidation
of a subgenomic FIV vector mRNA
We previously demonstrated that gag sequences are
necessary for encapsidation of FIV subgenomic vectors.When no gag was present, packaging was abolished and
marker gene transduction was absent. Inclusion of the
proximal 311 nucleotides of gag increased encapsidation
to nearly wild-type levels and resulted in high titer vectors
(Kemler et al., 2002). The mRNA of the vector with 311
nt of gag was packaged only slightly less efficiently than
the full-length virus transcript (Kemler et al., 2002). To
further characterize the proximal gag region, we con-
structed new vectors in which only the length of the
proximal gag fragment varies (GiNWF-Gn series, where
n = no. of gag nucleotides). Initially, gag was increased
from 311 to 350 nt (GiNWF-G350) or decreased to 270 nt
(GiNWF-G270), as illustrated in Fig. 1A. To enable robust
comparison with our prior data (Kemler et al., 2002), a
vector with previously determined encapsidation efficiency
(GiNWF-G144) was included in this analysis. The two
transfer vectors with the longest gag fragments also have a
frameshift generated by a single-nucleotide insertion at
position 298 of gag to prevent expression of potentially
interfering Gag protein fragments. Encapsidation efficien-
cies of mutant mRNAs derived from vectors GiNWF-G0,
-G144, -G270, -G311, and -G350 were analyzed in a
competitive assay (Kemler et al., 2002) that measures the
relative encapsidation efficiencies (REEs) of co-expressed
wild-type (CT5efs) and mutant RNAs (GiNWF-Gn). The
benefits of a directly competitive assay are that the same
Gag-Pol precursor pools and nascent particles are available
to the intracellular viral RNAs and that analysis of both
RNAs within the same cellular and virion samples obviates
problems with intersample variations accrued incrementally
during transfection, RNA recovery, and RPAs (McBride
and Panganiban, 1996). CT5efs is a full-length proviral
clone with a 29 nt env-frameshifting (‘‘efs’’) oligonucleo-
tide insertion in the SU domain. It was used rather than
CT5 to generate the wild-type mRNA to eliminate FIV
Env-induced cell lysis, which is prominent in 293T cells
via CXCR4-induced fusion (Poeschla and Looney, 1998),
and which could contaminate virion pellets with intracel-
lular RNA. CT5efs provides all virion proteins necessary
for packaging of its own mRNA and of the subgenomic
vector mRNAs. Cellular RNA and RNA from virion
particles pelleted through sucrose cushions were isolated.
Virion RNA was extracted from equivalent amounts of
viral particles, as determined by RT assay. RNAs were
then subjected to an RNase protection assay (RPA) with a
32P-labeled riboprobe that distinguishes between the wild-
type (CT5efs) and mutant (GiNWF-Gn) RNAs. The REE
of the mutant was determined by calculating the ratio of
mutant RNA to wild-type RNA in the virion, relative to
the ratio of the two RNAs in the cytoplasm (Kemler et al.,
2002; McBride et al., 1997). Each virion RNA was
analyzed in two different amounts (1 and 3). The
calculated REEs in each figure correspond to the particular
experiment shown in the figures. A summary of mean
REEs derived from multiple experiments is shown in Table
1. CT5efs and the gag-variant vector plasmids transcribed
Fig. 1. The proximal 230 nt of gag are necessary for efficient encapsidation of FIV subgenomic RNAs. (A) Schematic representation of pCT5efs and pGiNWF-
Gn constructs. (B) RPA of a competitive encapsidation experiment in which wild-type CT5efs was cotransfected with GiNWF-G0, -G144, -G270, -G311, or
-G350 into 293T cells. Cellular RNA and viral RNA were subjected to an RPA with a 32P-labeled riboprobe complementary to the central DNA flap region
(pSPT-FLAP). Protected RNA species are 358 nt for all GiNWF-Gn constructs and 296 nt for CT5efs. (C) RPA of a competitive encapsidation experiment
in which wild-type CT5efs was cotransfected with GiNWF-G0, -G144, -G190, -G230, -G270, -G311 into 293T cells. Riboprobe pSPT-FLAP was used.
Relative encapsidation efficiency (REE) was determined by calculating the ratio of mutant RNA to wild-type RNA in the virion, relative to the ratio in the
two RNAs in the cytoplasm (Kemler et al., 2002).
I. Kemler et al. / Virology 327 (2004) 111–120 113similar amounts of RNA (Fig. 1B, cellular RNA, compare
upper and lower bands in lanes 3–7). Consistent with
previous data (Kemler et al., 2002), when no gag sequen-
ces were present in the vector (GiNWF-G0), RNA pack-
aging was abolished (Fig. 1B, lanes 9 and 10). There was
little difference observed between vectors having 270 nt of
gag (REE = 0.94; lanes 13 and 14), 311 nt of gag (REE =
0.88; lanes 15 and 16), or 350 nt of gag (REE = 0.96;
lanes 17 and 18).
The finding that 270 nt of gag sequences conferred an
REE of 0.94 prompted study of additional truncations.
GiNWF-G230 and GiNWF-G190 have 230 and 190 nt,
respectively, of gag sequence (Fig. 1A). As shown in Fig.
1C, a transfer vector with 230 nt of gag is optimal, resulting
in an REE of 1.05 (lanes 16 and 17). Further deletion of gag
sequences to 190 nt reduced packaging to a REE of 0.67
(lanes 14 and 15). As previously seen (Kemler et al., 2002),
a vector with only 144 nt of gag sequences was furtherimpaired in mRNA packaging (Fig. 1B, lanes 11 and 12;
Fig. 1C, lanes 12 and 13). These results clearly identify
nucleotide 230 as the right-hand boundary of gag sequences
necessary for optimal encapsidation.
To determine whether the length of the gag fragment has
a corresponding effect on vector transduction efficiencies,
CrFK cells were infected with RT-normalized viral stocks of
VSV-G-pseudotyped vectors GiNWF-G0, -G144, -G190,
-G230, -G270, -G311, and the number of GFP-expressing
cells was determined by FACS analysis (Fig. 2). GiNWF-
G230 had a transduction efficiency of 2.37  106 TU/ml F
1.76  105 exceeding GiNWF-G311 (1.22  106 TU/ml F
1.71  105) and -G270 (1.61  106 TU/ml F 1.76  105).
As expected, GiNWF-G0 transduced very poorly. The
GiNWF-G144 vector nevertheless appreciably transduces,
although with a lower efficiency. Thus, the encapsidation
efficiencies and transduction efficiencies of the subgenomic
vectors correlate very well.
Table 1
Relative encapsidation efficiencies
Vector REE Provirus REE
GiNWF-GO 0.03 F 0.01 CT5-G0 0.10 F 0.06
GiNWF-G144 0.28 F 0.15 CT5-G144 0.20
GiNWF-G190 0.67 CT5-G190 0.64
GiNWF-G230 1.24 F 0.27 CT5-G230 0.95 F 0.03
GiNWF-G270 0.94 F 0.01 CT5-G270 0.75
GiNWF-G311 0.86 F 0.02
GiNWF-G350 0.96 CT5-G350 0.78
GiNWF-G45-230 0.20 F 0.14 CT5-G45-230 0.16 F 0.05
GiNWF-G34-230 0.17 F 0.04 CT5-G34-230 0.20 F 0.02
GiNWF-G23-230 0.28 F 0.00
GiNWF-G13-230 0.37 F 0.02 CT5-G13-230 0.52
The relative encapsidation efficiencies (REE) of the mutant vector or
proviral RNAs were determined by calculating the ratio of mutant RNA to
wild-type RNA in the virion, relative to the ratio of the two RNAs in the
cytoplasm. Calculations of standard deviations are based on results of two
to four independent experiments.
Fig. 2. Infectivity determinations for FIV vectors with different lengths of
gag fragment. CrFK cells were infected with RT activity-normalized viral
stocks of VSV-G pseudotyped vectors GiNWF-G0, -G144, -G190, -G230,
-G270, -G311. GFP-expressing cells were analyzed by FACS (Loewen et al.,
2003) and titers were expressed as the mean F SD of four independent
experiments.
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packaging of a genomic proviral RNA
In the GiNWF-Gn subgenomic vectors, the gag fragment
is followed by the Rev-responsive element (RRE), a juxta-
position that could influence encapsidation by resulting in
artificial secondary structures. Therefore, here and else-
where in these studies, we tested our conclusions about
the gag sequences in a second context: full-length provi-
ruses in which only the gag fragment was altered (Fig. 3A).
The packaging efficiencies of the mutant CT5-Gn provi-
ruses were analyzed in a competitive assay with the wild-
type CT5efs provirus. The mutant proviruses showed REEs
similar to those of corresponding mutant subgenomic vec-
tors (compare Fig. 3B with Figs. 1B and C). Absence of gag
sequences in the provirus completely abolished encapsida-
tion (REE 0.07, Fig. 3B, lanes 9 and 10), whereas inclusion
of the first 230 nt of gag resulted in the highest mRNA
packaging (REE 0.95, lanes 14 and 15). Longer gag frag-
ments (CT5-G270, CT5-G350) as well as shorter gag frag-
ments (CT5-G190, CT5-G144) had a negative influence on
mRNA encapsidation. These data (Figs. 1 and 3), in which
firm agreement was observed in both the full-length virus
and subgenomic vector contexts, establish definitively the
presence of an important packaging determinant in the first
230 nt of the FIV gag gene.
Our results disagree with Browning et al. (2003b), who
concluded that 100 bp of gag in conjunction with the 5V
UTR are sufficient for efficient FIV RNA encapsidation,
and that RNA is detectably packaged even in the absence of
any gag. Important methodological differences include the
use of the slot blot technique in the latter study to measure
RNAs, which does not confine measurements to single size-
specific bands as in the preferable RPAs used in our study.
In addition, the experimental design was a noncompetitive
encapsidation assay, where wild-type and mutant RNAs are
expressed in separate transfections (Browning et al., 2003b).
In contrast, we used a directly competitive encapsidationassay, which measures the relative encapsidation efficien-
cies of wild-type and mutant RNAs co-expressed within the
same cell (Kemler et al., 2002; McBride and Panganiban,
1996).
Short deletions at the 5V end of the FIV gag gene drastically
impair FIV RNA encapsidation
We established previously that in FIV deletions between
the major SD and the gag, ATG start did not significantly
attenuate encapsidation (Kemler et al., 2002). Having now
further mapped the 3V boundary of the gag determinant to
nt 230 with the 3V to 5V truncations, we used 5V to 3V gag
deletions to determine whether sequences in the 5V prox-
imal gag gene contributed to RNA packaging. New sub-
genomic vectors containing incremental forward 5V!3V
deletions starting at the gag ATG were made (GiNWF-
G45-230, -G90-230, -G135-230, -G180-230, Fig. 4A).
Testing of the three vectors with the longest deletions,
GiNWF-G90-230 (Fig. 4B, lanes 6 and 7), -G135-230, and
-G180-230 (data not shown) showed that mRNA encapsi-
dation was completely abolished, comparable to GiNWF-
G0. Only GiNWF-G45-230 resulted in appreciable mRNA
packaging (REE 0.12, lanes 4 and 5). Similar results were
obtained when these gag mutants were placed in the
context of a provirus (data not shown). Genomic RNA
from proviral clones CT5-G90efs, CT5-G135efs, and CT5-
G0efs was absent from viral particles. In contrast, CT5-
G45-230efs-derived RNA was encapsidated with a REE of
0.18 (Fig. 4C, lanes 10 and 11). These results show that
the first 90 nt of gag contain an absolutely essential
encapsidation determinant. However, the results did not
clearly define a left-hand boundary of packaging determi-
nants in gag because the GiNWF-G45-230 subgenomic
vector and the corresponding proviral clone CT5-G45-230
showed a fivefold lower encapsidation efficiency than the
wild-type provirus CT5efs. Therefore, more precise dele-
tions were made at the 5V end of gag, with the shortest
Fig. 3. The proximal 230 nt of gag are necessary for efficient encapsidation of FIV proviral clones. (A) Schematic representation of CT5efs and CT5-Gefs
clones, proviral clones with either all of gag deleted (CT5-G0efs) or with increasing amounts of gag (CT5-G144efs, -G190efs, -G230efs, -G350efs). (B) RPA
of a competitive encapsidation experiment. Wild-type CT5efs was cotransfected with the CT5-Gefs mutants into 293T cells. Cellular RNA and viral RNAwere
subjected to an RPA with a 32P-labeled riboprobe complementary to genome nucleotides 1847–2094 (pSPT-CT5MP). Protected RNA species are 247 nt for
CT5efs and 193 nt for CT5-Gefs clones. Relative encapsidation efficiencies are indicated at the bottom.
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-G34-230, Fig. 4A). Reducing further the degree of trun-
cation at the 5V end by incrementally restoring gag
sequences improved encapsidation of the vector mRNA
(Fig. 4B) as well as their corresponding proviral RNAs
(Fig. 4C). The mutants with either 45 or 34 nt of gag
sequence deleted showed comparable relative encapsida-
tion efficiencies (GiNWF-G45-230: 0.09, GiNWF-G34-
230: 0.14, Fig. 4B, lanes 21–24; and CT5-G45-230efs:
0.18, CT5-G34-230efs: 0.18, Fig. 4C, lanes 10–13). In-
clusion of an additional 11 nt, GiNWF-G23-230, further
increased packaging to 0.28 (Fig. 4B, lanes 25 and 26).
Surprisingly, restoration of 10 more nucleotides to
GiNWF-G23-230, resulting in GiNWF-G13-230 (a vector
with only the 13 most 5V nt of gag deleted), reduced RNA
encapsidation threefold compared to wild-type (REE =
0.35, Fig. 4B, lanes 27 and 28). Similarly, packaging of
the corresponding proviral RNA CT5-G13-230efs was
reduced twofold (Fig. 4C, lanes 14 and 15). These results
suggest that the most proximal 5V end of gag contributes
significantly to FIV mRNA packaging.
All the mutant subgenomic vectors (GiNWF-G) and the
corresponding proviral clones (CT5-G) harboring 5V!3V
deletions in gag analyzed so far (Fig. 4) contain a gag
gene truncated at position 230. In order to rigorously test
the contribution of proximal gag sequences in FIV mRNA
encapsidation, we next tested full-length proviral clones
having only 13 nt (CT5D13), 23 nt (CT5D23) or 90 nt(CT5D90) deleted at the 5V end of gag (Fig. 5A). These
clones were otherwise identical to the wild-type provirus
CT5efs. Cellular and viral RNAs were analyzed with a
riboprobe that spans the major splice donor and therefore
detects both unspliced genomic and spliced subgenomic
RNAs. Genomic mRNA with a 13 nt (CT5D13) or 23 nt
(CT5D23) deletion at the 5V end was packaged twofold
less efficiently than the wild-type CT5efs genomic RNA
(Fig. 5B, lanes 7–10). In CT5D90, which has the first 90
nt of the gag ORF deleted, a dramatic reduction in
packaging was observed with an REE of 0.17 (lanes 11
and 12). Thus, the 5V end of gag, particularly the first 90
nt, contains an indispensable determinant for mRNA
encapsidation. This element tolerates little alteration be-
cause a deletion as small as 13 nt (GiNWF-G13-230, CT5-
G13-230efs, CT5D13) has a strong effect on packaging.
These experiments establish a strong left-hand boundary of
the gag determinant.
This gag determinant might promote folding of RNA
secondary structure favorable for either Gag polyprotein
recognition or RNA dimerization. It is also possible that gag
sequences are part of a bipartite RNA packaging signal that
includes leader sequences such as R or U5, which we
previously have shown to be important for RNA packaging.
The gag determinant is necessary but not sufficient for
packaging because vector RNAs lacking leader sequences
are not encapsidated (Kemler et al., 2002). In HIV-1, a novel
RNA conformation was recently found that contains a long
Fig. 4. Requirement of the proximal 90 nt of FIV gag for encapsidation. (A) Schematic representation of GiNWF-Gn clones. Subgenomic FIV transfer vector
GiNWF-G230 was used to introduce increasing deletions beginning at the gag ATG start codon. (B) RPA of a competitive encapsidation experiment. Wild-type
CT5efs was cotransfected with GiNWF-G45-230 and GiNWF-G90-230 (lanes 1–7) or with GiNWF-G0, -G45-230, G34-230, G23-230, G13-230, -G0 (lanes
12–30) into 293T cells. Cellular RNA and viral RNAwere subjected to an RPA with a 32P-labeled riboprobe complementary to the central DNA flap (pSPT-
FLAP). Protected RNA species are 358 nt for all GiNWF-G clones and 296 nt for CT5efs. (C) RPA of a competitive encapsidation experiment. Wild-type
CT5efs was cotransfected with CT5-G0efs, -G45-230efs, -G90-230efs, -G135-230efs, -G230efs into 293T cells. Cellular RNA and viral RNAwere subjected
to an RPAwith a 32P-labeled riboprobe complementary to genome nucleotides 1847–2094 (pSPT-CT5MP). Protected RNA species are 247 nt for CT5efs and
193 nt for CT5-Gefs clones.
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sequences including the gag initiation codon (Abbink and
Berkhout, 2003).
The proximal 90 nt of gag might facilitate interactions of
viral RNA with Gag polyproteins involved in particle
formation by adopting a specific RNA secondary structure.
Recombinant HIV-1 Gag polyprotein shows strong in vitro
binding to the proximal 170 nt of gag measured by RNA gel
mobility shift assays (Berkowitz et al., 1993; Luban and
Goff, 1991). Binding is most probably mediated by RNA
secondary structure, similarly to binding of nucleocapsid
(NC) to the stem-loop structure SL3 in the HIV leader (De
Guzman et al., 1998).
Whether packaging and dimerization are clearly linked
processes has been controversial (Swanstrom and Wills,
1997). One model of HIV-1 dimerization involves a
‘‘kissing-loop’’ mechanism and proposes that RNA dimer-
ization is initiated by the SL1 loop palindrome sequencevia the formation of regular Watson–Crick base pairs. In
FIV, however, an analogous kissing-loop mechanism has
not been found, nor does modeling of RNA secondary
structures reveal a stem-loop structure containing a palin-
dromic loop. A second dimerization model for HIV-1
suggests that a tetra-stranded RNA structure, formed by
G-rich RNA sequences, results in RNA dimerization. In
vitro dimerization studies showed that guanine tracts in
HIV-1 gag were required for dimerization (Awang and
Sen, 1993; Haddrick et al., 1996; Sundquist and Heaphy,
1993), although later evidence suggested that the G-quar-
tets are not required in vivo for dimerization or packaging
(Haddrick et al., 1996; Russell et al., 2003). In FIV, two
G-rich elements with potential to form quartets can be
found in proximal gag. The first element is from nucleo-
tides 3 to 6 of gag and the second is found at position 70
to 75. As the first 90 nucleotides of gag contain a
determinant absolutely required for RNA encapsidation,
Fig. 5. Contribution of proximal gag sequences to encapsidation of full-length viral genomic mRNAs. (A) Schematic representation of CT5efs, CT5D13efs,
CT5D23efs, and CT5D90efs. (B) RPA of a competitive encapsidation experiment. Wild-type CT5efs was cotransfected with CT5D13, CT5D23, or CT5D90
into 293T cells. Cellular and virion RNAs were subjected to an RPA with a 32P-labeled riboprobe complementary to genome nucleotides 359–740 (pSPT-
CT5BN). Lengths of protected fragments are CT5efs genomic RNA 382 nt, CT5D13, CT5D23, CT5D90 genomic RNA 266 nt, all spliced RNAs 244 nt. Lane
6, mock-transfected cells.
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FIV RNA dimerization and encapsidation through the
formation of G-quartets.
The present results are the most detailed analysis yet of
gag packaging determinants in a lentivirus. Maintenance
of 350 or more nt of gag in HIV-1 transfer vectors has
been effective in gene therapy applications (Dull et al.,
1998), but the basis for the requirement has not been well
investigated. Although RNA stem-loops SL1 to SL4 in
HIV-1 have been examined in many encapsidation anal-
yses, surprisingly few studies (Buchschacher and Panga-
niban, 1992; Luban and Goff, 1994; Parolin et al., 1994)
have characterized the HIV-1 gag determinant. Luban and
Goff (1994) showed that an RNA lacking the first 40 nt
of the gag coding sequence had a greatly impaired
capacity of RNA packaging. However, a minimal gag
sequence requirement for packaging or transduction was
not defined. In another report, titers of HIV transfer
vectors encoding a selectable marker gene having 53 or
722 bp of gag were analyzed. The vector with 722 nt of
gag sequence produced moderately higher titers in this
system, but packaging of those vector RNAs was not
examined (Buchschacher and Panganiban, 1992). The
third of these studies found that inclusion of 40 or 653
nt of gag sequence in the vector increased the efficiency
of gene transfer by 16- and 32-fold, respectively (Parolin
et al., 1994). This increase was partly due to increased
packaging of vector RNA.
It is clear from the present data that deletions close to the
5V end of FIV gag have a strong negative influence on FIV
genome RNA encapsidation. Inclusion of the proximal 230nt of gag is optimal for genomic RNA packaging and
transduction efficiency of a FIV vector. Establishing a
right-hand boundary for this element will optimize FIV-
based lentiviral vectors. The 230 nt of gag are the only
sequences remaining in overlap with the packaging plasmid,
and this overlap can eventually be eliminated by synony-
mous nucleotide changes in gag.Materials and methods
Plasmid construction
Numbering of nucleotides follows Talbott et al. (1989).
All mutants were confirmed by automated DNA sequenc-
ing. pCT5efs is a variant of wild-type FIV expression
construct pCT5 (Poeschla and Looney, 1998; Poeschla
et al., 1998) with an env frame-shifting (efs) oligonucle-
otide insertion (29 bp) in the SU domain at nt 7176.
GiNWF-Gn constructs are FIV vector plasmids that con-
tain, from 5V to 3V, the hybrid U3-substituted promoter of
pCT5, R, U5, leader sequence, varying amounts of gag
sequence (n = no. of gag nucleotides), the Rev response
element (RRE), a sequence containing the FIV central
polypurine tract (cPPT) and the central termination sequence
(CTS) (Whitwam et al., 2001), the human CMV immediate
early promoter, egfp, an internal ribosomal entry site (IRES),
neoR, the woodchuck hepatitis virus post-transcriptional
regulatory element (WPRE), and the 3V long terminal repeat
(LTR). The cPPT-CTS combination is also referred to as the
central DNA flap, as the strand initiations and terminations
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structure at the completion of FIV reverse transcription.
GiNWF-G0, GiNWF-G144, GiNWF-G311, and GiNWF-
G407 were described previously (Kemler et al., 2002). The
other GiNWF-G constructs were generated by PCR with the
sense primer FIV11842 (5V-GCTTAGGGTTAGGCG-
TTTTGCGCTGC-3V) and one of the following SphI-tailed
antisense primers: FIV818-SphAS (5V-ATATGCATGCG-
TACTAACCAACCTTAGTTGATC-3V) for GiNWF-G190,
FIV858-SphAS (5V-ATATGCATGCGTACGCTAGATC-
CAAATTTTTCTC-3V) for GiNWF-G230, FIV 898-SphAS
(5V-ATATGCATGCGTACCAAAGACTTTTAATGTCAC-
3V) for GiNWF-G270, FIV978-SphAS (5V-ATATG-
CATGCGTACAGTGTCTAATCCCATTTGAG-3V) for
GiNWF-G350. The PCR products were restricted with MluI
and SphI and ligated to the 7208 bp MluI–SphI backbone of
GiNWF-G313. All plasmids were sequenced.
GiNWF-G clones containing incremental 5V! 3V dele-
tions in gag were generated by PCR with the antisense
primer FIV858SphAS (5V-ATATGCATGCGTACGCTA-
GATCCAAATTTTTCTC-3V) and one of the following
sense primers: FIV-Nla640 (5V-ATATCATGCAGGGGC-
GAGATTGGAAAATG-3V) for GiNWF-G13-230, FIV-
Nla650 (5V-ATATCATGATTGGAAAATGGCCATTAAG-
3V) for GiNWF-G23-230, FIV-Nla661 (5V-ATATCATGGC-
CATTAAGAGATGTAG-3V) for GiNWF-G34-230, FIV-
Nla672 (5V-ATATCATGATGTAGTAATGTTGCTGTAGG-
3V) for GiNWF-G45-230, FIV-Nla717 (5V-ATATCATGTG-
GAGAAGGGAATTTCAG-3V) for GiNWF-G90-230, FIV-
Nla762 (5V-ATATCATGTACAGGACGAGAACCTGG-3V)
for GiNWF-G135-230, FIV-Nla858 (5V-ATATCAT-
GAAGGTTGGTTATTTGCG) for GiNWF-G180-230.
GiNWF-G230 was used as a template. PCR fragments
were restricted with NlaIII, blunted and restricted with
SphI. Fragments were cloned into GiNWF-G0 between
position 627 (BsiWI site blunted) and position 632 (Sph
site). All plasmids were sequenced. CT5-G13-230efs was
constructed by isolating a 3656 bp SphI (blunted)–NotI
fragment from GiNWF-G13-230 and ligating it to a 7574
bp PstI (blunted)–NotI fragment derived from CT5efs. The
other CT5-Gefs clones were made correspondingly.
CT5D13 was constructed by inserting a 1117 bp MluI–
BstXI from GiNWF-G13-230 into CT5efs restricted with
MluI and EcoRI (10019 bp) together with an 875 bp
BspMI–EcoRI fragment from CT5efs and a 258 bp
BstXI–BspMI fragment from GiNWF-G1226, containing
a frameshifting mutation at position 298 of gag to prevent
expression of potentially interfering Gag protein fragments.
CT5D23 and CT5D90 were made correspondingly. All
plasmids were sequenced.
Plasmids used as templates for production of riboprobes
were constructed as follows. pSPT-CT5MP was generated
by inserting a 247 bp PflMI–MseI fragment from position
1847 to 2094 of CT5efs into pSPT18 (Roche) digested
with SmaI. The resulting plasmid was linearized with SacI.
The protected RNA species are 247 nt for CT5efs and 193nt for CT5-Gefs clones. pSPT-CT5BN was generated by
inserting a 382 bp NarI–BstXI fragment from position 359
to 740 of CT5efs into pSPT19 (Roche) digested with SmaI
and AccI. The resulting plasmid was linearized with
HindIII. The protected RNA species are 382 nt for CT5
genomic RNA, 266 and 103 nt for CT5D13 genomic
RNA, 266 and 93 nt for CT5D23 genomic RNA, 266 nt
for CT5D90 genomic RNA, and 244 nt for all spliced
RNAs. pSPT-FLAP was described in Kemler et al. (2002).
Protected RNA species are 358 nt for all GiNWF-G clones
and 296 nt for CT5efs.
Cell culture and transfections
293T and Crandell feline kidney (CrFK) cells were
cultured in Dulbecco’s modified Eagle medium with 10%
fetal calf serum. Transient transfections were performed by
the calcium phosphate coprecipitation method. In compet-
itive encapsidation assays, 7.5 Ag of pCT5efs (wild-type)
and 7.5 Ag of mutant plasmid were cotransfected.
RNA isolation
Forty-two hours after transfection cellular RNA was
isolated with Trizol (Invitrogen) according to the manufac-
turer’s protocol. Viral particles were purified from the medi-
um by removing cell debris by centrifugation at 828  g in a
Sorvall table top centrifuge for 10 min and filtering the
clarified supernatant through a 0.45 Am filter. The virus
was then pelleted through a 20% sucrose cushion for 2 h at
112700  g in a SW28 rotor. The viral pellet was resus-
pended in TNE buffer (10 mM Tris, pH 7.5, 100 mMNaCl, 1
mM EDTA) and aliquots were stored at 80 jC. Viral
particle production was measured by a reverse transcriptase
assay. Viral RNA was isolated by disrupting the particles in
1% SDS, proteinase K (100 Ag/ml) at 37 jC for 30 min in the
presence of 10 Ag yeast RNA. After two extractions with
phenol (pH 4.5)–chloroform, RNAwas ethanol precipitated
in the presence of 0.3 M sodium acetate. Both cellular and
viral RNAs were treated with 10U RNase-free DNase I in a
buffer containing 20 mM Tris, pH 8.0, 10 mM MgCl2, and
40U RNase inhibitor (Roche) at 37 jC for 30 min. The
reaction was terminated by adding an equal volume of a 2
stop buffer (0.4% SDS, 0.6 M sodium acetate, 20 mM
EDTA). The RNA was extracted with phenol–chloroform
and precipitated with ethanol. The concentration of cellular
RNA was determined by measuring the spectrophotometric
absorption at 260 nm.
RNase protection assay
32P-labeled riboprobes were synthesized by in vitro
transcription of linearized plasmids, using SP6 RNA po-
lymerase (Roche), a32P-rUTP (800 Ci/mmol), and 5 AM
unlabeled rUTP. Riboprobes were purified from 6% poly-
acrylamide-8 M urea gels before use. The RPA was
I. Kemler et al. / Virology 327 (2004) 111–120 119performed with a commercially available kit (Ambion)
according to the manufacturer’s protocol. Five micrograms
of cellular RNA or different amounts of viral RNA
supplemented with 2 Ag yeast RNA was mixed with 5 
105 cpm of 32P-labeled probe in 10 Al hybridization buffer
and incubated at 42 jC for 12 h. Unhybridized regions
were then digested with 0.37U RNase A and 15U RNase
T1 for 30 min at 37 jC. Protected fragments were
precipitated, resuspended in RNA loading buffer, and
separated on 6% polyacrylamide–8 M urea gels. For size
determination, a32P-dCTP labeled fragments of pBR322
digested with MspI were run in parallel. Protected RNA
species were quantified by PhosphorImager analysis (Mo-
lecular Dynamics).
Vector transduction efficiencies and RT assay
VSV-G pseudotyped vectors were produced in 293T
cells by transfecting 3 Ag of GiNWF-G plasmid together
with 1 Ag pMD.G (VSV-G) and 3 Ag FP93 (packaging
plasmid, provides Gag/Pol proteins, lacks all viral sequen-
ces upstream of gag; Loewen et al., 2003). Transduction
efficiencies were determined as described by Loewen et al.
(2003). CrFK cells were infected with 10-fold serial dilu-
tions of RT-normalized VSV-G pseudotyped GiNWF-G
vectors. Forty-eight hours later, cells were trypsinized, fixed
in 1% formalin–PBS, and analyzed for GFP-expressing
cells by fluorescence-activated flow cytometry (FACS). The
RT assay was performed as described in Kemler et al.
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